Sensitivity-based analytical approaches to support human absolute bioavailability studies

Calculation and Mitigation of Isotopic Interferences in Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability Studies

(2012) Huidong Gu et al.   ANALYTICAL CHEMISTRY

A Mild and Reliable Method to Label Enveloped Virus with Quantum Dots by Copper-Free Click Chemistry

(2012) Jian Hao et al.   ANALYTICAL CHEMISTRY

Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

(2012) David W. Boulton et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations

(2012) Xiaohui (Sophia) Xu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Overcoming bioanalytical challenges in an Onglyza®intravenous [14C]microdose absolute bioavailability study with accelerator MS

(2012) Xiaohui (Sophia) Xu et al.   Bioanalysis

When opportunity met aspirational goals: accelerator MS, microdosing and absolute bioavailability studies

(2012) Mark E Arnold et al.   Bioanalysis

Analytical validation of accelerator mass spectrometry for pharmaceutical development

(2010) Bradly D Keck et al.   Bioanalysis

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

(2009) A. Fura et al.   DRUG METABOLISM AND DISPOSITION

Biological accelerator mass spectrometry at Uppsala University

(2008) Mehran Salehpour et al.   APPLIED RADIATION AND ISOTOPES

The utility of microdosing over the past 5 years

(2008) Graham Lappin et al.   Expert Opinion on Drug Metabolism & Toxicology